Royalty Pharma (NASDAQ:RPRX) presented its fourth quarter and full year 2025 financial results on February 11, 2026, highlighting double-digit growth across key metrics and an expanding focus on ...
Quarterly Performance Highlights Royalty Pharma reported impressive growth in its key financial metrics for Q2 2025, with Portfolio Receipts reaching $727 million, representing a 20% year-over-year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results